Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today.
The annual Pharmaceutical Innovation Index measures pretty much the only thing that matters in pharma: did you take assets to market (and to patients) in the past 5 years, and did you do so successfully? Any measures of productivity that miss those two parameters are surrogates, and incredibly misleading.
However, take a look at these numbers, which compare performance of the top 11 in the 2018 Index with the lowest 10. Perhaps no surprise that the biggest spenders had a much greater chance of an approval in any year over the 5 years, and therefore derived much more of their revenue in 2017 from products launched in that period. But, we’re still only talking about 1 approval per year for the top 11 companies, on average.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.